Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Nektar Therapeutics (NKTR)
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Nektar Therapeutics since year 2005.
(See page 1 of this report.) Table 2 shows the detailed insider transactions of Nektar Therapeutics since 2005.
The reporting company's ticker symbol is NKTR. The reporting company's CIK number is 906709.
The total value of stock buying since 2005 is $1,622,185.
The total value of stock sales since 2005 is $225,427,253.
The total value of stock option exercises since 2005 is $69,093,937.
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2017-11-07 | Doberstein Stephen K (SVP & Chief Scientific Officer) | Sale | 75,409 | 25.78 | 1,944,044 |
| 2017-11-07 | Doberstein Stephen K (SVP & Chief Scientific Officer) | Option Ex | 75,409 | 9.53 | 718,647 |
| 2017-11-07 | Hora Maninder (SVP Pharma Dev & Mfg Ops) | Option Ex | 34,600 | 18.10 | 626,260 |
| 2017-11-06 | Doberstein Stephen K (SVP & Chief Scientific Officer) | Sale | 20,914 | 24.98 | 522,431 |
| 2017-11-06 | Doberstein Stephen K (SVP & Chief Scientific Officer) | Option Ex | 20,914 | 9.53 | 199,310 |
| 2017-11-06 | Hora Maninder (SVP Pharma Dev & Mfg Ops) | Sale | 5,117 | 25.07 | 128,283 |
| 2017-11-06 | Hora Maninder (SVP Pharma Dev & Mfg Ops) | Option Ex | 5,117 | 10.69 | 54,700 |
| 2017-11-01 | Robin Howard W (President & CEO) | Sale | 83,334 | 23.57 | 1,964,182 |
| 2017-11-01 | Robin Howard W (President & CEO) | Option Ex | 83,334 | 11.34 | 945,007 |
| 2017-10-09 | Robin Howard W (President & CEO) | Sale | 83,333 | 24.20 | 2,016,658 |
| 2017-10-09 | Robin Howard W (President & CEO) | Option Ex | 83,333 | 11.34 | 944,996 |
| 2017-10-05 | Doberstein Stephen K (SVP & Chief Scientific Officer) | Sale | 43,677 | 24.97 | 1,090,614 |
| 2017-10-05 | Doberstein Stephen K (SVP & Chief Scientific Officer) | Option Ex | 43,677 | 9.53 | 416,241 |
| 2017-10-05 | Hora Maninder (SVP Pharma Dev & Mfg Ops) | Sale | 7,583 | 25.00 | 189,575 |
| 2017-10-05 | Hora Maninder (SVP Pharma Dev & Mfg Ops) | Option Ex | 7,583 | 10.69 | 81,062 |
| 2017-10-02 | Labrucherie Gil M (SVP & Chief Financial Officer) | Sale | 120,000 | 24.45 | 2,934,000 |
| 2017-10-02 | Labrucherie Gil M (SVP & Chief Financial Officer) | Option Ex | 120,000 | 11.34 | 1,360,800 |
| 2017-10-02 | Gergel Ivan P. (SVP & Chief Medical Officer) | Sale | 56,704 | 24.21 | 1,372,803 |
| 2017-10-02 | Gergel Ivan P. (SVP & Chief Medical Officer) | Option Ex | 56,704 | 11.04 | 626,012 |
| 2017-09-29 | Gergel Ivan P. (SVP & Chief Medical Officer) | Sale | 43,296 | 24.04 | 1,040,835 |
| 2017-09-29 | Gergel Ivan P. (SVP & Chief Medical Officer) | Option Ex | 43,296 | 11.04 | 477,987 |
| 2017-09-22 | Lingnau Lutz (Director) | Sale | 5,000 | 21.97 | 109,850 |
| 2017-09-22 | Kuebler Christopher A (Director) | Sale | 4,000 | 21.86 | 87,440 |
| 2017-09-21 | Chess Robert (Director) | Sale | 6,400 | 21.72 | 139,008 |
| 2017-09-06 | Robin Howard W (President & CEO) | Sale | 83,333 | 21.54 | 1,794,992 |
| 2017-09-06 | Robin Howard W (President & CEO) | Option Ex | 83,333 | 11.34 | 944,996 |
| 2017-08-16 | Doberstein Stephen K (SVP & Chief Scientific Officer) | Sale | 1,701 | 19.32 | 32,863 |
| 2017-08-16 | Hora Maninder (SVP Pharma Dev & Mfg Ops) | Sale | 2,956 | 19.32 | 57,109 |
| 2017-08-16 | Thomsen Jillian B. (SVP & Chief Accounting Officer) | Sale | 2,648 | 19.32 | 51,159 |
| 2017-08-16 | Nicholson John (SVP & Chief Operating Officer) | Sale | 3,177 | 19.32 | 61,379 |
| 2017-08-16 | Labrucherie Gil M (SVP & Chief Financial Officer) | Sale | 3,177 | 19.32 | 61,379 |
| 2017-08-16 | Gergel Ivan P. (SVP & Chief Medical Officer) | Sale | 1,997 | 19.32 | 38,582 |
| 2017-08-16 | Robin Howard W (President & CEO) | Sale | 91,714 | 19.29 | 1,768,704 |
| 2017-08-16 | Robin Howard W (President & CEO) | Option Ex | 83,334 | 11.34 | 945,007 |
| 2017-08-10 | Whitfield Roy A (Director) | Buy | 35,000 | 17.95 | 628,250 |
| 2017-07-18 | Gergel Ivan P. (SVP & Chief Medical Officer) | Sale | 54,920 | 21.10 | 1,158,812 |
| 2017-07-18 | Gergel Ivan P. (SVP & Chief Medical Officer) | Option Ex | 54,920 | 11.04 | 606,316 |
| 2017-07-14 | Lingnau Lutz (Director) | Sale | 30,000 | 20.76 | 622,800 |
| 2017-07-14 | Lingnau Lutz (Director) | Option Ex | 30,000 | 14.26 | 427,800 |
| 2017-07-12 | Gergel Ivan P. (SVP & Chief Medical Officer) | Sale | 36,691 | 21.09 | 773,813 |
| 2017-07-12 | Gergel Ivan P. (SVP & Chief Medical Officer) | Option Ex | 36,691 | 11.04 | 405,068 |
| 2017-07-11 | Gergel Ivan P. (SVP & Chief Medical Officer) | Sale | 8,389 | 21.04 | 176,504 |
| 2017-07-11 | Gergel Ivan P. (SVP & Chief Medical Officer) | Option Ex | 8,389 | 11.04 | 92,614 |
| 2017-06-26 | Krivulka Joseph J (Director) | Option Ex | 15,000 | 8.37 | 125,549 |
| 2017-06-07 | Nicholson John (SVP & Chief Operating Officer) | Sale | 101,700 | 19.24 | 1,956,707 |
| 2017-06-07 | Nicholson John (SVP & Chief Operating Officer) | Option Ex | 150,000 | 6.34 | 951,000 |
| 2017-05-16 | Doberstein Stephen K (SVP & Chief Scientific Officer) | Sale | 1,701 | 19.55 | 33,254 |
| 2017-05-16 | Hora Maninder (SVP Pharma Dev & Mfg Ops) | Sale | 2,959 | 19.55 | 57,848 |
| 2017-05-16 | Thomsen Jillian B. (SVP & Chief Accounting Officer) | Sale | 2,651 | 19.55 | 51,827 |
| 2017-05-16 | Nicholson John (SVP & Chief Operating Officer) | Sale | 3,146 | 19.55 | 61,504 |
| 2017-05-16 | Labrucherie Gil M (SVP & Chief Financial Officer) | Sale | 3,179 | 19.55 | 62,149 |
| 2017-05-16 | Gergel Ivan P. (SVP & Chief Medical Officer) | Sale | 1,450 | 19.55 | 28,347 |
| 2017-05-16 | Robin Howard W (President & CEO) | Sale | 8,388 | 19.55 | 163,985 |
| 2017-05-15 | Chess Robert (Director) | Sale | 5,000 | 19.79 | 98,950 |
| 2017-05-15 | Chess Robert (Director) | Option Ex | 5,000 | 8.37 | 41,849 |
| 2017-04-17 | Chess Robert (Director) | Sale | 5,000 | 18.72 | 93,600 |
| 2017-04-17 | Chess Robert (Director) | Option Ex | 5,000 | 8.37 | 41,849 |
| 2017-04-07 | Lingnau Lutz (Director) | Sale | 7,000 | 20.05 | 140,350 |
| 2017-04-05 | Doberstein Stephen K (SVP & Chief Scientific Officer) | Sale | 100,000 | 21.70 | 2,170,000 |
| 2017-04-05 | Doberstein Stephen K (SVP & Chief Scientific Officer) | Option Ex | 100,000 | 9.53 | 952,999 |
| 2017-04-05 | Hora Maninder (SVP Pharma Dev & Mfg Ops) | Sale | 180,000 | 21.70 | 3,906,000 |
| 2017-04-05 | Hora Maninder (SVP Pharma Dev & Mfg Ops) | Option Ex | 180,000 | 13.70 | 2,466,000 |
| 2017-04-05 | Kuebler Christopher A (Director) | Sale | 15,000 | 21.88 | 328,200 |
| 2017-04-05 | Kuebler Christopher A (Director) | Option Ex | 15,000 | 8.37 | 125,549 |
| 2017-03-20 | Thomsen Jillian B. (SVP & Chief Accounting Officer) | Sale | 112,500 | 19.69 | 2,215,125 |
| 2017-03-20 | Thomsen Jillian B. (SVP & Chief Accounting Officer) | Option Ex | 112,500 | 9.28 | 1,043,437 |
| 2017-03-15 | Whitfield Roy A (Director) | Option Ex | 14,000 | 8.37 | 117,179 |
| 2017-03-14 | Chess Robert (Director) | Sale | 5,000 | 15.41 | 77,050 |
| 2017-03-14 | Chess Robert (Director) | Option Ex | 5,000 | 8.37 | 41,849 |
| 2017-03-03 | Labrucherie Gil M (SVP & Chief Financial Officer) | Sale | 32,494 | 15.21 | 494,233 |
| 2017-03-03 | Labrucherie Gil M (SVP & Chief Financial Officer) | Option Ex | 32,494 | 7.79 | 253,128 |
| 2017-03-02 | Labrucherie Gil M (SVP & Chief Financial Officer) | Sale | 167,506 | 15.15 | 2,537,715 |
| 2017-03-02 | Labrucherie Gil M (SVP & Chief Financial Officer) | Option Ex | 167,506 | 6.34 | 1,061,988 |
| 2017-02-21 | Lingnau Lutz (Director) | Sale | 30,000 | 13.08 | 392,400 |
| 2017-02-21 | Lingnau Lutz (Director) | Option Ex | 30,000 | 5.14 | 154,200 |
| 2017-02-16 | Doberstein Stephen K (SVP & Chief Scientific Officer) | Sale | 1,261 | 13.14 | 16,569 |
| 2017-02-16 | Hora Maninder (SVP Pharma Dev & Mfg Ops) | Sale | 2,195 | 13.14 | 28,842 |
| 2017-02-16 | Thomsen Jillian B. (SVP & Chief Accounting Officer) | Sale | 1,965 | 13.14 | 25,820 |
| 2017-02-16 | Nicholson John (SVP & Chief Operating Officer) | Sale | 3,237 | 13.14 | 42,534 |
| 2017-02-16 | Labrucherie Gil M (SVP & Chief Financial Officer) | Sale | 2,359 | 13.14 | 30,997 |
| 2017-02-16 | Gergel Ivan P. (SVP & Chief Medical Officer) | Sale | 1,457 | 13.14 | 19,144 |
| 2017-02-16 | Robin Howard W (President & CEO) | Sale | 8,636 | 13.14 | 113,477 |
| 2017-02-10 | Nicholson John (SVP & Chief Operating Officer) | Option Ex | 45,000 | 4.65 | 209,250 |
| 2017-02-08 | Robin Howard W (President & CEO) | Sale | 87,500 | 13.04 | 1,141,000 |
| 2017-02-08 | Robin Howard W (President & CEO) | Option Ex | 87,500 | 4.65 | 406,875 |
| 2017-02-03 | Nicholson John (SVP & Chief Operating Officer) | Sale | 8,505 | 12.48 | 106,142 |
| 2017-02-03 | Nicholson John (SVP & Chief Operating Officer) | Option Ex | 8,505 | 4.65 | 39,548 |
| 2017-02-02 | Nicholson John (SVP & Chief Operating Officer) | Sale | 66,495 | 12.38 | 823,208 |
| 2017-02-02 | Nicholson John (SVP & Chief Operating Officer) | Option Ex | 66,495 | 4.65 | 309,201 |
| 2017-01-17 | Robin Howard W (President & CEO) | Sale | 87,500 | 12.35 | 1,080,625 |
| 2017-01-17 | Robin Howard W (President & CEO) | Option Ex | 87,500 | 4.65 | 406,875 |
| 2016-12-07 | Robin Howard W (President & CEO) | Sale | 87,500 | 12.24 | 1,071,000 |
| 2016-12-07 | Robin Howard W (President & CEO) | Option Ex | 87,500 | 4.65 | 406,875 |
| 2016-11-17 | Robin Howard W (President & CEO) | Sale | 87,500 | 13.87 | 1,213,625 |
| 2016-11-17 | Robin Howard W (President & CEO) | Option Ex | 87,500 | 4.65 | 406,875 |
| 2016-11-16 | Doberstein Stephen K (SVP & Chief Scientific Officer) | Sale | 670 | 13.96 | 9,353 |
| 2016-11-16 | Hora Maninder (SVP Pharma Dev & Mfg Ops) | Sale | 1,654 | 13.96 | 23,089 |
| 2016-11-16 | Thomsen Jillian B. (SVP & Chief Accounting Officer) | Sale | 1,986 | 13.96 | 27,724 |
| 2016-11-16 | Nicholson John (SVP & Chief Operating Officer) | Sale | 1,654 | 13.96 | 23,089 |
| 2016-11-16 | Labrucherie Gil M (SVP & Chief Financial Officer) | Sale | 1,654 | 13.96 | 23,089 |
| 2016-11-16 | Gergel Ivan P. (SVP & Chief Medical Officer) | Sale | 848 | 13.96 | 11,838 |
| 2016-11-16 | Robin Howard W (President & CEO) | Sale | 5,958 | 13.96 | 83,173 |
| 2016-10-24 | Greer R Scott (Director) | Buy | 15,000 | 13.50 | 202,500 |
| 2016-10-04 | Robin Howard W (President & CEO) | Sale | 87,500 | 17.06 | 1,492,750 |
| 2016-10-04 | Robin Howard W (President & CEO) | Option Ex | 87,500 | 4.65 | 406,875 |
| 2016-09-23 | Whitfield Roy A (Director) | Option Ex | 46,000 | 6.22 | 286,120 |
| 2016-09-16 | Kuebler Christopher A (Director) | Sale | 7,500 | 19.13 | 143,475 |
| 2016-09-15 | Lingnau Lutz (Director) | Sale | 9,000 | 19.06 | 171,540 |
| 2016-09-15 | Lingnau Lutz (Director) | Option Ex | 15,000 | .00 | 0 |
| 2016-09-15 | Krivulka Joseph J (Director) | Option Ex | 15,000 | .00 | 0 |
| 2016-09-15 | Kuebler Christopher A (Director) | Option Ex | 15,000 | .00 | 0 |
| 2016-09-15 | Chess Robert (Director) | Sale | 12,000 | 19.21 | 230,520 |
| 2016-09-15 | Chess Robert (Director) | Option Ex | 15,000 | .00 | 0 |
| 2016-09-15 | Winger Dennis L (Director) | Option Ex | 15,000 | .00 | 0 |
| 2016-09-15 | Greer R Scott (Director) | Option Ex | 15,000 | .00 | 0 |
| 2016-09-15 | Whitfield Roy A (Director) | Option Ex | 15,000 | .00 | 0 |
| 2016-09-01 | Robin Howard W (President & CEO) | Sale | 87,500 | 17.83 | 1,560,124 |
| 2016-09-01 | Robin Howard W (President & CEO) | Option Ex | 87,500 | 4.65 | 406,875 |
| 2016-08-16 | Doberstein Stephen K (SVP & Chief Scientific Officer) | Sale | 1,336 | 17.56 | 23,460 |
| 2016-08-16 | Hora Maninder (SVP Pharma Dev & Mfg Ops) | Sale | 3,305 | 17.56 | 58,035 |
| 2016-08-16 | Thomsen Jillian B. (SVP & Chief Accounting Officer) | Sale | 3,971 | 17.56 | 69,730 |
| 2016-08-16 | Nicholson John (SVP & Chief Operating Officer) | Sale | 3,317 | 17.56 | 58,246 |
| 2016-08-16 | Labrucherie Gil M (SVP & Chief Financial Officer) | Sale | 3,305 | 17.56 | 58,035 |
| 2016-08-16 | Gergel Ivan P. (SVP & Chief Medical Officer) | Sale | 1,685 | 17.56 | 29,588 |
| 2016-08-16 | Robin Howard W (President & CEO) | Sale | 11,817 | 17.56 | 207,506 |
| 2016-08-01 | Chess Robert (Director) | Sale | 5,000 | 17.26 | 86,300 |
| 2016-08-01 | Chess Robert (Director) | Option Ex | 5,000 | 5.15 | 25,750 |
| 2016-07-11 | Thomsen Jillian B. (SVP & Chief Accounting Officer) | Sale | 100,000 | 15.09 | 1,509,000 |
| 2016-07-11 | Thomsen Jillian B. (SVP & Chief Accounting Officer) | Option Ex | 100,000 | 4.65 | 465,000 |
| 2016-07-01 | Chess Robert (Director) | Sale | 5,000 | 14.10 | 70,500 |
| 2016-07-01 | Chess Robert (Director) | Option Ex | 5,000 | 5.15 | 25,750 |
| 2016-06-01 | Chess Robert (Director) | Sale | 5,000 | 15.50 | 77,500 |
| 2016-06-01 | Chess Robert (Director) | Option Ex | 5,000 | 5.15 | 25,750 |
| 2016-05-17 | Doberstein Stephen K (SVP & Chief Scientific Officer) | Sale | 339 | 13.58 | 4,603 |
| 2016-05-17 | Hora Maninder (SVP Pharma Dev & Mfg Ops) | Sale | 835 | 13.58 | 11,339 |
| 2016-05-17 | Thomsen Jillian B. (SVP & Chief Accounting Officer) | Sale | 724 | 13.58 | 9,831 |
| 2016-05-17 | Nicholson John (SVP & Chief Financial Officer) | Sale | 856 | 13.58 | 11,624 |
| 2016-05-17 | Labrucherie Gil M (SVP & General Counsel) | Sale | 836 | 13.58 | 11,352 |
| 2016-05-17 | Gergel Ivan P. (SVP & Chief Medical Officer) | Sale | 432 | 13.58 | 5,866 |
| 2016-05-17 | Robin Howard W (President & CEO) | Sale | 2,170 | 13.58 | 29,468 |
| 2016-05-16 | Doberstein Stephen K (SVP & Chief Scientific Officer) | Option Ex | 875 | .00 | 0 |
| 2016-05-16 | Hora Maninder (SVP Pharma Dev & Mfg Ops) | Option Ex | 2,167 | .00 | 0 |
| 2016-05-16 | Thomsen Jillian B. (SVP & Chief Accounting Officer) | Option Ex | 1,875 | .00 | 0 |
| 2016-05-16 | Nicholson John (SVP & Chief Financial Officer) | Option Ex | 2,167 | .00 | 0 |
| 2016-05-16 | Labrucherie Gil M (SVP & General Counsel) | Option Ex | 2,167 | .00 | 0 |
| 2016-05-16 | Gergel Ivan P. (SVP & Chief Medical Officer) | Option Ex | 1,250 | .00 | 0 |
| 2016-05-16 | Robin Howard W (President & CEO) | Option Ex | 5,625 | .00 | 0 |
| 2016-04-25 | Lingnau Lutz (Director) | Sale | 15,000 | 16.27 | 244,050 |
| 2016-04-25 | Lingnau Lutz (Director) | Option Ex | 15,000 | 8.37 | 125,549 |
| 2016-03-09 | Thomsen Jillian B. (SVP & Chief Accounting Officer) | Sale | 15,000 | 11.79 | 176,850 |
Insider trading activities including stock purchases, stock sales, and option exercises of NKTR listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Nektar Therapeutics (symbol NKTR, CIK number 906709) see the Securities and Exchange Commission (SEC) website.